GHRP-6

GHRP-6 has the sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂, featuring D-amino acids to resist enzymatic degradation. The C-terminal amidation further increases its stability in circulation. It is synthesized by Fmoc solid-phase peptide synthesis and purified by preparative HPLC to >95 % purity. Mass spectrometry confirms correct sequence and molecular weight.

GHRP-6 binds to the ghrelin receptor (growth-hormone secretagogue receptor) on pituitary somatotrophs and hypothalamic neurons, triggering GH release. It also stimulates release of GH-releasing hormone from the hypothalamus, amplifying the GH pulse. Unlike ghrelin, GHRP-6 induces minimal appetite effects at investigational doses. Elevations in GH are observed within 30–60 minutes of subcutaneous injection.

The peptide is evaluated primarily for its capacity to increase natural GH and IGF-1 levels. In human studies, GHRP-6 produced robust GH pulses and sustained IGF-1 increases compared with baseline. Subjects showed improved markers of protein synthesis and lean-body-mass maintenance. Research continues into its potential for age-related decline, sarcopenia, and metabolic health.

Reported adverse events include transient hunger stimulation, mild water retention, and injection-site discomfort. No clinically significant changes in cortisol or prolactin were observed in short-term trials. Long-term safety beyond several weeks has not been established. Recommended monitoring includes GH/IGF-1 levels and basic metabolic panels.

GHRP-6 is assembled via Fmoc solid-phase peptide synthesis on a resin support, incorporating D-amino acids at specified positions. After cleavage, it is purified by HPLC to research-grade purity. Mass spectrometry confirms its identity and integrity. Production adheres to peptide-compounding standards.

GHRP-6 is classified for research use only and is not approved by the U.S. FDA, EMA, or other major regulatory bodies. It cannot be marketed or prescribed clinically. Investigators may obtain it under investigational peptide regulations, which vary by jurisdiction. No therapeutic formulations are available.

Human trials have used 100–300 µg subcutaneously two to three times daily. Injections are typically spaced 30 minutes before meals. No standardized dosing guidelines exist outside these study protocols. All administration should follow institutional review–board–approved designs.

Do restrict use to IRB-approved research settings with medical oversight.Do monitor GH, IGF-1, and basic metabolic panels during treatment.Don’t combine with other GH secretagogues without justification.Don’t use during pregnancy, lactation, or active malignancy.

Q: How quickly does GH rise?A: GH peaks within 30–60 minutes after injection.Q: Does it affect appetite?A: Mild hunger stimulation can occur but is generally transient.Q: Are cortisol or prolactin levels affected?A: No significant changes have been reported in short-term studies.